These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

374 related articles for article (PubMed ID: 21707463)

  • 21. [Evidence on the key role of the metabotrobic glutamatergic receptors in the pathogenesis of schizophrenia: a "breakthrough" in pharmacological treatment].
    Pannese R; Minichino A; Pignatelli M; Delle Chiaie R; Biondi M; Nicoletti F
    Riv Psichiatr; 2012; 47(2):149-69. PubMed ID: 22622251
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Significance of NMDA receptor-related glutamatergic amino acid levels in peripheral blood of patients with schizophrenia.
    Ohnuma T; Arai H
    Prog Neuropsychopharmacol Biol Psychiatry; 2011 Jan; 35(1):29-39. PubMed ID: 20828596
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of NMDA receptor modulators on a blood-brain barrier in vitro model.
    Neuhaus W; Freidl M; Szkokan P; Berger M; Wirth M; Winkler J; Gabor F; Pifl C; Noe CR
    Brain Res; 2011 Jun; 1394():49-61. PubMed ID: 21549356
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Multiprobe molecular imaging of an NMDA receptor hypofunction rat model for glutamatergic dysfunction.
    Kosten L; Verhaeghe J; Verkerk R; Thomae D; De Picker L; Wyffels L; Van Eetveldt A; Dedeurwaerdere S; Stroobants S; Staelens S
    Psychiatry Res Neuroimaging; 2016 Feb; 248():1-11. PubMed ID: 26803479
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Manipulation of brain kynurenines: glial targets, neuronal effects, and clinical opportunities.
    Schwarcz R; Pellicciari R
    J Pharmacol Exp Ther; 2002 Oct; 303(1):1-10. PubMed ID: 12235226
    [TBL] [Abstract][Full Text] [Related]  

  • 26. NMDA Receptors in glia.
    Verkhratsky A; Kirchhoff F
    Neuroscientist; 2007 Feb; 13(1):28-37. PubMed ID: 17229973
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Reduced microglial immunoreactivity for endogenous NMDA receptor agonist quinolinic acid in the hippocampus of schizophrenia patients.
    Gos T; Myint AM; Schiltz K; Meyer-Lotz G; Dobrowolny H; Busse S; Müller UJ; Mawrin C; Bernstein HG; Bogerts B; Steiner J
    Brain Behav Immun; 2014 Oct; 41():59-64. PubMed ID: 24886967
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Neuropharmacology of quinolinic and kynurenic acids.
    Stone TW
    Pharmacol Rev; 1993 Sep; 45(3):309-79. PubMed ID: 8248282
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Significance of dysfunctional glutamatergic transmission for the development of psychotic symptoms.
    Pietraszek M
    Pol J Pharmacol; 2003; 55(2):133-54. PubMed ID: 12926541
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Schizophrenia: more evidence for less glutamate.
    Morrison PD; Pilowsky LS
    Expert Rev Neurother; 2007 Jan; 7(1):29-31. PubMed ID: 17187494
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Linking phencyclidine intoxication to the tryptophan-kynurenine pathway: Therapeutic implications for schizophrenia.
    Fujigaki H; Mouri A; Yamamoto Y; Nabeshima T; Saito K
    Neurochem Int; 2019 May; 125():1-6. PubMed ID: 30731185
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Peripheral and cerebral metabolic abnormalities of the tryptophan-kynurenine pathway in a murine model of major depression.
    Laugeray A; Launay JM; Callebert J; Surget A; Belzung C; Barone PR
    Behav Brain Res; 2010 Jun; 210(1):84-91. PubMed ID: 20153778
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Animal model of schizophrenia: dysfunction of NMDA receptor-signaling in mice following withdrawal from repeated administration of phencyclidine.
    Nabeshima T; Mouri A; Murai R; Noda Y
    Ann N Y Acad Sci; 2006 Nov; 1086():160-8. PubMed ID: 17185514
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Role of astrocytes in alterations of glutamatergic neurotransmission in schizophrenia].
    Kolomeets NS
    Zh Nevrol Psikhiatr Im S S Korsakova; 2015; 115(1):110-117. PubMed ID: 25945378
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Glutamatergic (N-methyl-D-aspartate receptor) hypofrontality in schizophrenia: too little juice or a miswired brain?
    Marek GJ; Behl B; Bespalov AY; Gross G; Lee Y; Schoemaker H
    Mol Pharmacol; 2010 Mar; 77(3):317-26. PubMed ID: 19933774
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The kynurenine pathway in schizophrenia and bipolar disorder.
    Erhardt S; Schwieler L; Imbeault S; Engberg G
    Neuropharmacology; 2017 Jan; 112(Pt B):297-306. PubMed ID: 27245499
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Glutamatergic neurotransmission in schizophrenics].
    Bleich S; Bleich K; Wiltfang J; Maler JM; Kornhuber J
    Fortschr Neurol Psychiatr; 2001 Sep; 69 Suppl 2():S56-61. PubMed ID: 11533851
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mitochondria, metabolic disturbances, oxidative stress and the kynurenine system, with focus on neurodegenerative disorders.
    Sas K; Robotka H; Toldi J; Vécsei L
    J Neurol Sci; 2007 Jun; 257(1-2):221-39. PubMed ID: 17462670
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inflammation and the glutamate system in schizophrenia: implications for therapeutic targets and drug development.
    Müller N
    Expert Opin Ther Targets; 2008 Dec; 12(12):1497-507. PubMed ID: 19007319
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role of Kynurenine Metabolism Pathway Activation in Major Depressive Disorders.
    Savitz J
    Curr Top Behav Neurosci; 2017; 31():249-267. PubMed ID: 27221627
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.